Factor VIII medicines: no clear and consistent evidence of difference in risk of inhibitor development between classes EMA concludes review of human factor VIII medicines authorised in EU The European Medicines Agency (EMA) has...
We are saddened to inform that Alnylam Pharmaceuticals has reported a fatal thrombotic event in a patient with haemophilia A without inhibitors in the Phase 2 open-label extension (OLE) study of fitusiran. Fitusiran is an...
The 2017 Annual Conference of the European Haemophilia Consortium (EHC) will take place in Vilnius, Lithuania from October 6th to October 8th. Apply to attend by July 28th and take advantage of the early...
Every three years since 2009, the European Haemophilia Consortium (EHC) has conducted surveys amongst its 45 national haemophilia member organisations to determine the extent to which the European Principles of Haemophilia Care and the...
A paper has just been published in the official journal of the Centers of Disease Control and Prevention (CDC) relating to the death of 2 people with inherited bleeding disorders (one was a female...
Read their conclusion here .
On April 19th, the EHC marked World Haemophilia Day in Strasbourg, France with an event dedicated to the latest Wildbad Kreuth IV consensus recommendations on optimal haemophilia care throughout Europe! These recommendations are the...
As part of its continues efforts to improve the quality of life of people living with rare bleeding disorders throughout Europe, the European Haemophilia Consortium (EHC) has developed and launched the Procurement of Affordable...
We are saddened to share that in the past week, the EHC has been informed of the death of a person with haemophilia with inhibitors, who was on the clinical trial (HAVEN 1) with...
